Computational methods for analysis and inference of kinase/inhibitor relationships

Frontiers in Genetics

Volumn 5, Issue JUN, 2014, Pages

  Ferrè, Fabrizio ^a   Palmeri, Antonio ^a   Helmer Citterich, Manuela ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chemogenomics; Drug design and development; Kinase activity modulation; Kinase inhibitors; Kinase inhibitor inference

Indexed keywords

CYCLIN DEPENDENT KINASE 2; DASATINIB; G PROTEIN COUPLED RECEPTOR INHIBITOR; IMATINIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BAYESIAN LEARNING; BINDING AFFINITY; BINDING SITE; COMPUTER ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFICACY; DRUG TARGETING; IC 50; MACHINE LEARNING; MEASUREMENT ACCURACY; PHYSICAL CHEMISTRY; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SUPPORT VECTOR MACHINE;

EID: 84906247317     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00196     Document Type: Short Survey

References (41)

1. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045. doi: 10.1038/nbt.2017
2. Anderson, P. C., De Sapio, V., Turner, K. B., Elmer, S. P., Roe, D. C., and Schoeniger, J. S. (2012). Identification of binding specificity-determining features in protein families. J. Med. Chem. 55, 1926-1939. doi: 10.1021/jm200979x
3. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H. et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315. doi: 10.1042/BJ20070797
4. Bamborough, P., Drewry, D., Harper, G., Smith, G. K., and Schneider, K. (2008). Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914. doi: 10.1021/jm8011036
5. Berman, H. M., Kleywegt, G. J., Nakamura, H., and Markley, J. L. (2013). How community has shaped the Protein Data Bank. Structure 21, 1485-1491. doi: 10.1016/j.str.2013.07.010
6. Bryant, D. H., Moll, M., Finn, P. W., and Kavraki, L. E. (2013). Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome. PLoS Comput. Biol. 9:e1003087. doi: 10.1371/journal.pcbi.1003087
7. Brylinski, M., and Skolnick, J. (2010). Cross-reactivity virtual profiling of the human kinome by X-react(KIN): a chemical systems biology approach. Mol. Pharm. 7, 2324-2333. doi: 10.1021/mp1002976
8. Caffrey, D. R., Lunney, E. A., and Moshinsky, D. J. (2008). Prediction of specificity-determining residues for small-molecule kinase inhibitors. BMC Bioinformatics 9:491. doi: 10.1186/1471-2105-9-491
9. Cao, D. S., Zhou, G. H., Liu, S., Zhang, L. X., Xu, Q. S., He, M. et al. (2013). Large-scale prediction of human kinase/inhibitor interactions using protein sequences and molecular topological structures. Anal. Chim. Acta 792, 10-18. doi: 10.1016/j.aca.2013.07.003
10. Chahrour, O., Cairns, D., and Omran, Z. (2012). Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev. Med. Chem. 12, 399-411. doi: 10.2174/138955712800493915
11. Chen, Y. F., Hsu, K. C., Lin, S. R., Wang, W. C., Huang, Y. C., and Yang, J. M. (2010). SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. Nucleic Acids Res. 38, W424-W430. doi: 10.1093/nar/gkq480
12. Chiu, Y. Y., Lin, C. T., Huang, J. W., Hsu, K. C., Tseng, J. H., You, S. R. et al. (2013). KIDFamMap: a database of kinase/inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms. Nucleic Acids Res. 41, D430-D440. doi: 10.1093/nar/gks1218
13. Chuaqui, C., Deng, Z., and Singh, J. (2005). Interaction profiles of protein kinase/inhibitor complexes and their application to virtual screening. J. Med. Chem. 48, 121-133. doi: 10.1021/jm049312t
14. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G. et al. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051. doi: 10.1038/nbt.1990
15. Fabian, M. A., Biggs W. H. III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G. et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336. doi: 10.1038/nbt1068
16. Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A. N. et al. (2007). A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. U.S.A. 104, 20523-20528. doi: 10.1073/pnas.0708800104
17. Fedorov, O., Muller, S., and Knapp, S. (2010). The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166-169. doi: 10.1038/nchembio.297
18. Garuti, L., Roberti, M., and Bottegoni, G. (2010). Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 17, 2804-2821. doi: 10.2174/092986710791859333
19. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A. et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107. doi: 10.1093/nar/gkr777
20. Gavrin, L. K., and Saiah, E. (2013). Approaches to discover non-ATP site kinase inhibitors. Med. Chem. Commun . 4, 41-51. doi: 10.1039/c2md20180a
21. Goldstein, D. M., Gray, N. S., and Zarrinkar, P. P. (2008). High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391-397. doi: 10.1038/nrd2541
22. Huang, D., Zhou, T., Lafleur, K., Nevado, C., and Caflisch, A. (2010). Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics 26, 198-204. doi: 10.1093/bioinformatics/btp650
23. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T. et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132. doi: 10.1038/nbt1358
24. Kim, J., Yoo, M., Kang, J., and Tan, A. C. (2013). K-Map: connecting kinases with therapeutics for drug repurposing and development. Hum. Genomics 7, 20. doi: 10.1186/1479-7364-7-20
25. Kuhn, M., Szklarczyk, D., Pletscher-Frankild, S., Blicher, T. H., von Mering, C., Jensen, L. J. et al. (2014). STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res. 42, D401. doi: 10.1093/nar/gkt1207
26. Lapins, M., and Wikberg, J. E. (2010). Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. BMC Bioinformatics 11:339. doi: 10.1186/1471-2105-11-339
27. Liu, Y., and Gray, N. S. (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364. doi: 10.1038/nchembio799
28. Manallack, D. T., Pitt, W. R., Gancia, E., Montana, J. G., Livingstone, D. J., Ford, M. G. et al. (2002). Selecting screening candidates for kinase and G protein-coupled receptor targets using neural networks. J. Chem. Inf. Comput. Sci. 42, 1256-1262. doi: 10.1021/ci020267c
29. Mencher, S. K., and Wang, L. G. (2005). Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5:3. doi: 10.1186/1472-6904-5-3
30. Metz, J. T., Johnson, E. F., Soni, N. B., Merta, P. J., Kifle, L., and Hajduk, P. J. (2011). Navigating the kinome. Nat. Chem. Biol. 7, 200-202. doi: 10.1038/nchembio.530
31. Miduturu, C. V., Deng, X., Kwiatkowski, N., Yang, W., Brault, L., Filippakopoulos, P. et al. (2011). High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868-879. doi: 10.1016/j.chembiol.2011.05.010
32. Niijima, S., Shiraishi, A., and Okuno, Y. (2012). Dissecting kinase profiling data to predict activity and understand cross-reactivity of kinase inhibitors. J. Chem. Inf. Model. 52, 901-912. doi: 10.1021/ci200607f
33. Paricharak, S., Klenka, T., Augustin, M., Patel, U. A., and Bender, A. (2013). Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases. J. Cheminform. 5, 49. doi: 10.1186/1758-2946-5-49
34. Posy, S. L., Hermsmeier, M. A., Vaccaro, W., Ott, K. H., Todderud, G., Lippy, J. S. et al. (2011). Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54-66. doi: 10.1021/jm101195a
35. Punta, M., Coggill, P. C., Eberhardt, R. Y., Mistry, J., Tate, J., Boursnell, C. et al. (2012). The Pfam protein families database. Nucleic Acids Res. 40, D290-D301. doi: 10.1093/nar/gkr1065
36. Schürer, S. C., and Muskal, S. M. (2013). Kinome-wide activity modeling from diverse public high-quality data sets. J. Chem. Inf. Model. 53, 27-38. doi: 10.1021/ci300403k
37. Sutherland, J. J., Gao, C., Cahya, S., and Vieth, M. (2013). What general conclusions can we draw from kinase profiling data sets? Biochim. Biophys. Acta 1834, 1425-1433. doi: 10.1016/j.bbapap.2012.12.023
38. Tang, J., Szwajda, A., Shakyawar, S., Xu, T., Hintsanen, P., Wennerberg, K. et al. (2014). Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. J. Chem. Inf. Model. 54, 735-743. doi: 10.1021/ci400709d
39. Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A., and Hemmerle, H. (2004). Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243-257. doi: 10.1016/j.bbapap.2003.11.028
40. Xia, X., Maliski, E. G., Gallant, P., and Rogers, D. (2004). Classification of kinase inhibitors using a Bayesian model. J. Med. Chem. 47, 4463-4470. doi: 10.1021/jm0303195
41. Yabuuchi, H., Niijima, S., Takematsu, H., Ida, T., Hirokawa, T., Hara, T. et al. (2011). Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol. Syst. Biol. 7, 472. doi: 10.1038/msb.2011.5